The global “Vasopressin For Vasoplegic Shock Market Share”, size is expected to gain momentum by reaching USD 2,657.9 million by 2027, while exhibiting a stellar CAGR of 14.8% between 2020 and 2027. This is attributable to the increasing prevalence of cardiovascular surgeries that propels the demand for vasopressin for vasoplegic shock across the globe. This information is published by Fortune Business Insights, in its latest report, titled, “Vasopressin for Vasoplegic Shock Market Size, Share & COVID-19 Impact Analysis, By Application (Sepsis, Post Cardiac Surgery, and Others) Regional Forecast, 2020-2027.” The report further mentions that the market stood at USD 890.9 million in 2019.
Request a Sample Copy of the Research Report:
What does the Report Include?
The market report includes a detailed assessment of various drivers and restraints, opportunities, and challenges that the market will face during the projected horizon. Additionally, the report provides comprehensive insights into the regional developments of the market, affecting its growth during the forecast period. It includes information sourced from the advice of expert professionals from the industry by our research analysts using several research methodologies. The competitive landscape offers further detailed insights into strategies such as product launches, partnership, merger and acquisition, and collaborations adopted by the companies to maintain market stronghold between 2020 and 2027.
An Overview of the Impact of COVID-19 on this Market :
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.
For more information visit :
https://www.fortunebusinessinsights.com/vasopressin-for-vasoplegic-shock-market-104065
Rising Cardiac Syndrome Cases amid COVID-19 to Boost Growth
The recent spike in the cases of people suffering from the novel coronavirus disease is expected to surge the cardiac syndrome risk amongst people susceptible to contracting it. This is leading the pharmaceutical sector to focus on developing advanced vasopressin drugs for treatment purposes. This is expected to bode well for the growth of the global market in the near future.
Vasoplegia is a type of syndrome that involves pathologically low systemic vascular resistance. It further leads to reduced blood pressure amid presence of a raised cardiac output. The growing adoption of vasopressin for vasoplegic shock treatment is gaining popularity owing to its efficiency in treating the syndrome.
Quick Buy – Vasopressin for Vasoplegic Shock Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/104065
Table Of Content :
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Recent Industry Developments Such as Mergers & Acquisitions
- Regulatory Scenario for Key Countries
- New Product Launch
- Statistics on Prevalence of Cardiac Disorders for Key Countries/Regions
- Pipeline Analysis
Continue…
More Trending Topics from Fortune Business Insights :
Dentures Market Set for Rapid Growth and Trend by 2021-2026 | Covid-19 Analysis
Fitness Tracker Market Set for Rapid Growth and Trend by 2021-2026 | Covid-19 Analysis
DRIVING FACTORS
Increasing Incidence of Cardiovascular Surgeries to Augment Growth
According to the Centers for Disease Control and Prevention (CDC), every year about 340,000 Coronary Artery Bypass Grafting (CABG) procedures are performed in the U.S. The increasing number of cardiovascular surgeries propels the demand for vasopressin to control the blood flow. Additionally, the growing number of CABG procedures and sepsis patients are boosting the demand for innovative vasopressin treatment options. This is expected to bode well for the global vasopressin for vasoplegic shock market growth during the forecast period.
SEGMENTATION
Post Cardiac Surgery Segment Held 25.2% in 2019
The post cardiac segment, based on application, held a market share of about 25.2% in 2019 and is likely to gain momentum owing to the increasing number of cardiac surgeries that require efficient post-cardiac treatment globally.
REGIONAL INSIGHTS
Increasing Prevalence of Sepsis in North America to Favor Growth
Among all the regions, North America stood at USD 561.3 million in 2019 and is expected to hold the highest position in the global market in the forthcoming years. This is ascribable to the increasing prevalence of sepsis that drives the demand for advanced vasopressin for vasoplegic shock treatment procedures in the region.
The market in Europe is expected to experience a significant growth backed by surging investments in R&D by the government as well as major companies to develop advanced vasopressin for vasoplegic shock treatment between 2020 and 2027.
COMPETITIVE LANDSCAPE
Prominent Companies Focus on Investment in R&D Activities to Develop Innovative Vasopressin for Vasoplegic Shock
The global vasopressin for vasoplegic shock market is fragmented by the presence of key players that are focusing on raising investments to develop advanced vasopressin for vasoplegic shock treatment. Additionally, the major companies are striving to maintain their presence in the global marketplace by adopting strategies such as partnership, collaboration, and merger and acquisition to gain a competitive edge over their rivals during the forecast period.
Industry Development:
- April 2018 – Eagle Pharmaceuticals, Inc announced the approval of its new drug application, ANDA for 1ml vasopressin injection. The product is a original generic version of Endo International plc’s Vasostrict formulation.
List of the Companies Profiled in the Market:
- Endo International plc (Dublin, Ireland)
- AMOMED Pharma (Vienna, Austria)
- La Jolla Pharmaceutical Company (California, U.S.)
- Pfizer Inc. (New York, U.S.)
- Ferring Pharmaceuticals (Saint-Prex, Switzerland)
- Fresenius Kabi Canada (Toronto, Canada)
- Astellas Pharma (Tokyo, Japan)
- Eagle Pharmaceuticals, Inc. (New Jersey, U.S.)
- Others
Have Any Query? Ask Our Experts:
Global Vasopressin for Vasoplegic Shock Market Segmentation :
By Application
- Sepsis
- Post Cardiac Surgery
- Others
By Geography
- North America
- By Application
- By Country
- Europe
- By Application
- By Country/Sub-region
- Asia Pacific
- By Application
- By Country/Sub-region
- Latin America
- By Application
- By Country/Sub-region
- The Middle East & Africa
- By Application
- By Country/Sub-region
SECONDARY DATA SOURCES THAT WE REFER TO:
- Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
- Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
- Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics
- Industry journals and paid databases
SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:
- Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
- Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
- Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
- Number of procedures and average price of procedures
- Replacement rate and pricing of capital equipment
- Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
- Market & technological trends, new product developments, product pipeline.
About Us:
Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges
Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
